Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

Dr. Joshua Hare to Chair the Board

LA JOLLA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today the formation of a Medical Advisory Board to provide clinical guidance for the Company's development program of CDP-1050 for the treatment of heart failure.

The Medical Advisory Board will play an important supportive role in the design and oversight of the planned CDP-1050 Phase 2 clinical trial and assist in addressing regulatory and patients' welfare issues. It is composed of internationally recognized leaders in the field of heart failure; all of whom have extensive experience in the design and execution of clinical trials aimed at improved care of patients with heart failure.

CDP-1050 is being developed as a new therapeutic modality in the management of heart failure. It targets the redox-nitiric oxide imbalance, which is increasingly recognized as a major factor in poor myocardial contractile efficiency, the hallmark manifestation of this disorder.

The Medical Advisory Board is chaired by Joshua M. Hare, M.D., the Louis Lemberg Professor of Medicine, Chief of the Division of Cardiology, and Director of the Interdisciplinary Stem Cell Institute at University of Miami, Miller School of Medicine. He has pioneered the use of stem cell therapy to repair damaged hearts. Dr. Hare has authored and co-authored numerous peer-reviewed publications including a report on a multi-center clinical trial with oxypurinol, a modifier of cellular redox potential, in patients with symptomatic heart failure. He served as the principal investigator of that clinical trial. Dr. Hare has also authored a New England Journal of Medicine editorial on redox-nitric oxide balance in the cardiovascular system.

Other members of the Medical Advisory Board include:

Wilson S. Colucci, M.D., is the Thomas J. Ryan Professor of
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... 26, 2015  23andMe, the leading personal genetics company, ... as Privacy Officer and Corporate Counsel. Black brings a ... as well as health care regulations. As a member ... responsible for reviewing, updating and enhancing the company,s privacy ... abroad. She joined the company January 5, 2015 and ...
(Date:2/26/2015)... 2015   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today reported 2014 ... other key objectives, and financial guidance.  Synageva,s management ... 4:30 p.m. EST to review the financial results ... in today,s call by telephone, please dial (877) ...
(Date:2/26/2015)... , Feb. 26, 2015 Protiviti ( www.protiviti.com ... version of the Governance Portal , designed to ... and compliance (GRC) tasks across multiple business units and ... to help customers better align their controls with the ... Commission ) requirements. In response to client feedback, Protiviti ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3
... Therapeutics, Inc. (Nasdaq: NLTX ), a company focused ... today announced that it has received commitments from investors to ... aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., ... agent for the transaction. , , The net proceeds ...
... PRINCETON, N.J., July 8 DOR BioPharma, Inc. ... a late-stage biopharmaceutical company, announced today that it ... Lipid Polymer Micelle (LPM(TM)) technology for the improved ... EP 1460992, entitled "Stabilized Reverse Micelle Compositions and ...
... ... Services, Inc. announces the publication of a new white paper - ... Risk." This incisive resource provides guidelines on how to establish a ... business throughout the world. "The U.S. Foreign Corrupt Practices Act (FCPA): ...
Cached Biology Technology:Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement 2Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement 3Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement 4DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 2DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 3DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 4DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 5PharmSource Releases White Paper on Role of U.S. Foreign Corrupt Practices Act (FCPA) in the Bio/Pharma Industry 2PharmSource Releases White Paper on Role of U.S. Foreign Corrupt Practices Act (FCPA) in the Bio/Pharma Industry 3
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... Bloomington and eight collaborating institutions report in this ... live in rocks 2.8 kilometers below Earth's surface. ... uranium to convert water molecules to useable energy. ... of Earth's biosphere, the three-dimensional shell that encompasses ...
... Look no further than the air around you. It ... bacteria, according to a first-of-its-kind census of airborne microbes ... Energy's Lawrence Berkeley National Laboratory (Berkeley Lab). , ... the bacteria in air samples taken from the Texas ...
... By studying a gene earlier linked to deafness in humans, ... which components of the inner ear send messages to the ... 2006, issue of the journal Cell, published by Cell Press. ... are profoundly deaf. The animals' deafness results from an inability ...
Cached Biology News:Bacteria that use radiated water as food 2Bacteria that use radiated water as food 3Study finds the air rich with bacteria 2Study finds the air rich with bacteria 3Study finds the air rich with bacteria 4Critical hearing gene helps send auditory messages to brain 2Critical hearing gene helps send auditory messages to brain 3
... cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide White ... GAS. A potent inhibitor of MMP-2 that ... = 1.7 μM). Purity: ≥98% ... DMSO. Unstable in solution, reconstitute just prior ...
... Reacts with an early ... infection 3 hours post-infection exhibiting ... reaches peak intensity between 6-24 ... extremely intense coarsely granular staining. ...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Goat polyclonal to DRAK2...
Biology Products: